EQL PHARMA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.4 SEK | -0.23% |
|
+0.93% | +29.94% |
| Feb. 13 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
| Feb. 13 | EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
Sector
Drug Retailers
Calendar
2024-05-13
- Q4 2024 Earnings Release
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +29.94% | 116M | |
| -32.31% | 15.36B | |
| -36.57% | 10.16B | |
| +9.74% | 6.13B | |
| -10.81% | 6.01B | |
| -35.14% | 5.65B | |
| -0.73% | 4.71B | |
| +51.51% | 4.33B | |
| -11.96% | 3.58B | |
| -18.03% | 3.21B |
- Stock Market
- Equities
- EQL Stock
- News EQL Pharma AB
- EQL Pharma Out-licenses Mellozzan in Seven European Countries
